Limits...
Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS).

Steinhagen-Thiessen E, Bramlage P, Lösch C, Hauner H, Schunkert H, Vogt A, Wasem J, Jöckel KH, Moebus S - Cardiovasc Diabetol (2008)

Bottom Line: Thresholds of the ESC seem to be difficult to meet.A simple call for more aggressive treatment or higher patient compliance is apparently not enough to enhance the proportion of controlled patients.A shift towards a multifactorial treatment considering lifestyle interventions and pharmacotherapy to reduce weight and lipids may be the only way in a population where just to be normal is certainly not ideal.

View Article: PubMed Central - HTML - PubMed

Affiliation: Charité - Universitätsmedizin Berlin, Germany. elisabeth.steinhagen-thiessen@charite.de

ABSTRACT

Background: Current guidelines from the European Society of Cardiology (ESC) define low thresholds for the diagnosis of dyslipidemia using total cholesterol (TC) and LDL-cholesterol (LDL-C) to guide treatment. Although being mainly a prevention tool, its thresholds are difficult to meet in clinical practice, especially primary care.

Methods: In a nationwide study with 1,511 primary care physicians and 35,869 patients we determined the prevalence of dyslipidemia, its recognition, treatment, and control rates. Diagnosis of dyslipidemia was based on TC and LDL-C. Basic descriptive statistics and prevalence rate ratios, as well as 95% confidence intervals were calculated.

Results: Dyslipidemia was highly frequent in primary care (76% overall). 48.6% of male and 39.9% of female patients with dyslipidemia was diagnosed by the physicians. Life style intervention did however control dyslipidemia in about 10% of patients only. A higher proportion (34.1% of male and 26.7% female) was controlled when receiving pharmacotherapy. The chance to be diagnosed and subsequently controlled using pharmacotherapy was higher in male (PRR 1.15; 95%CI 1.12-1.17), in patients with concomitant cardiovascular risk factors, in patients with hypertension (PRR 1.20; 95%CI 1.05-1.37) and cardiovascular disease (PRR 1.46; 95%CI 1.29-1.64), previous myocardial infarction (PRR 1.32; 95%CI 1.19-1.47), and if patients knew to be hypertensive (PRR 1.18; 95%CI 1.04-1.34) or knew about their prior myocardial infarction (PRR 1.17; 95%CI 1.23-1.53).

Conclusion: Thresholds of the ESC seem to be difficult to meet. A simple call for more aggressive treatment or higher patient compliance is apparently not enough to enhance the proportion of controlled patients. A shift towards a multifactorial treatment considering lifestyle interventions and pharmacotherapy to reduce weight and lipids may be the only way in a population where just to be normal is certainly not ideal.

Show MeSH

Related in: MedlinePlus

Proportion of patients in different age groups being dyslipidemic as the the 2003 ESC guidelines. Total dyslipidemia is defined as either "lipid disorders yes" or "lipid lowering agent yes" or lab values compatible with the diagnosis of dyslipidemia as previously defined. Reference for each percent number given is the total number of patients in that age group indicted in the upper part of the figure.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2572156&req=5

Figure 1: Proportion of patients in different age groups being dyslipidemic as the the 2003 ESC guidelines. Total dyslipidemia is defined as either "lipid disorders yes" or "lipid lowering agent yes" or lab values compatible with the diagnosis of dyslipidemia as previously defined. Reference for each percent number given is the total number of patients in that age group indicted in the upper part of the figure.

Mentions: Dyslipidemia, based on the current ESC guideline definition, was a frequent condition in all age groups from 18 up to 100 years (Figure 1). While the proportion of dyslipidemic patients was low in the young age group (20.9% in male and 39.8% in female patients up to an age of 20 years) it peaked in the age group of 61 – 70 years in both genders with a gradual decline thereafter, more so in male than in female patients.


Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS).

Steinhagen-Thiessen E, Bramlage P, Lösch C, Hauner H, Schunkert H, Vogt A, Wasem J, Jöckel KH, Moebus S - Cardiovasc Diabetol (2008)

Proportion of patients in different age groups being dyslipidemic as the the 2003 ESC guidelines. Total dyslipidemia is defined as either "lipid disorders yes" or "lipid lowering agent yes" or lab values compatible with the diagnosis of dyslipidemia as previously defined. Reference for each percent number given is the total number of patients in that age group indicted in the upper part of the figure.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2572156&req=5

Figure 1: Proportion of patients in different age groups being dyslipidemic as the the 2003 ESC guidelines. Total dyslipidemia is defined as either "lipid disorders yes" or "lipid lowering agent yes" or lab values compatible with the diagnosis of dyslipidemia as previously defined. Reference for each percent number given is the total number of patients in that age group indicted in the upper part of the figure.
Mentions: Dyslipidemia, based on the current ESC guideline definition, was a frequent condition in all age groups from 18 up to 100 years (Figure 1). While the proportion of dyslipidemic patients was low in the young age group (20.9% in male and 39.8% in female patients up to an age of 20 years) it peaked in the age group of 61 – 70 years in both genders with a gradual decline thereafter, more so in male than in female patients.

Bottom Line: Thresholds of the ESC seem to be difficult to meet.A simple call for more aggressive treatment or higher patient compliance is apparently not enough to enhance the proportion of controlled patients.A shift towards a multifactorial treatment considering lifestyle interventions and pharmacotherapy to reduce weight and lipids may be the only way in a population where just to be normal is certainly not ideal.

View Article: PubMed Central - HTML - PubMed

Affiliation: Charité - Universitätsmedizin Berlin, Germany. elisabeth.steinhagen-thiessen@charite.de

ABSTRACT

Background: Current guidelines from the European Society of Cardiology (ESC) define low thresholds for the diagnosis of dyslipidemia using total cholesterol (TC) and LDL-cholesterol (LDL-C) to guide treatment. Although being mainly a prevention tool, its thresholds are difficult to meet in clinical practice, especially primary care.

Methods: In a nationwide study with 1,511 primary care physicians and 35,869 patients we determined the prevalence of dyslipidemia, its recognition, treatment, and control rates. Diagnosis of dyslipidemia was based on TC and LDL-C. Basic descriptive statistics and prevalence rate ratios, as well as 95% confidence intervals were calculated.

Results: Dyslipidemia was highly frequent in primary care (76% overall). 48.6% of male and 39.9% of female patients with dyslipidemia was diagnosed by the physicians. Life style intervention did however control dyslipidemia in about 10% of patients only. A higher proportion (34.1% of male and 26.7% female) was controlled when receiving pharmacotherapy. The chance to be diagnosed and subsequently controlled using pharmacotherapy was higher in male (PRR 1.15; 95%CI 1.12-1.17), in patients with concomitant cardiovascular risk factors, in patients with hypertension (PRR 1.20; 95%CI 1.05-1.37) and cardiovascular disease (PRR 1.46; 95%CI 1.29-1.64), previous myocardial infarction (PRR 1.32; 95%CI 1.19-1.47), and if patients knew to be hypertensive (PRR 1.18; 95%CI 1.04-1.34) or knew about their prior myocardial infarction (PRR 1.17; 95%CI 1.23-1.53).

Conclusion: Thresholds of the ESC seem to be difficult to meet. A simple call for more aggressive treatment or higher patient compliance is apparently not enough to enhance the proportion of controlled patients. A shift towards a multifactorial treatment considering lifestyle interventions and pharmacotherapy to reduce weight and lipids may be the only way in a population where just to be normal is certainly not ideal.

Show MeSH
Related in: MedlinePlus